Monday, April 25, 2011

Distance Learning Program on South Carolina Warnings Law Recorded at South Carolina Bar

Back in February, I posted that the South Carolina Bar asked if I would do a Distance Learning program based on my warnings article that was published in the January 2011 edition of South Carolina Lawyer, entitled "Products Liability Claims in South Carolina: What is South Carolina's Law on Warnings?"  I taped the segment this morning, and it was a great experience.  I spoke for about an hour on South Carolina warnings law.  I prepared some PowerPoint slides to illustrate certain points, and I anticipate that the program will also come with a copy of my January 2011 article for download by anyone who purchases it.

In short, I felt like a news anchor for about an hour.  The studio is set up so that you are sitting at a table and speaking on camera, with no "audience" per se.  This took a little getting used to, especially if you are more accustomed to presenting at public venues.  However, it went off without a hitch, and I enjoyed the preparation and experience.  Be on the lookout for it if you need CLE credit and want to do it in the comfort of your own home/office at your computer.

Most of my posts lately have been on various marketing and research projects that I have been working on.  However, I am going to try and post a "Case Brief" later this week so as to try and get back to some more substantive discussion.

Friday, April 15, 2011

Written Materials from DRI Presentation

I previously posted here a de-brief from my time at the 2011 DRI Products Liability Conference in New Orleans last week.  As indicated in the post, I had the opportunity to speak at the Agricultural, Construction, Mining, and Industrial Equipment ("ACMIE") Specialized Litigation Group breakout session on Thursday.  My task was to present on the "top 10" ACMIE cases from 2010. 

Although this is the "South Carolina Products Liability Law Blog" and it focuses on South Carolina law, I thought that you may find the materials to be of interest if you work with this type of equipment.  The written materials from my presentation can be found at this link, and the materials include a brief of Holst v. KCI Konecranes Int’l Corp., 699 S.E.2d 715 (S.C. Ct. App. 2010) , a South Carolina case from 2010 that I blogged about here when the South Carolina Court of Appeals issued its opinion.

You are probably wondering my "methodology" (for you Daubert v. Merrell Dow Pharmaceuticals fans) for singling out these ten ACMIE cases.  This was no small task.  Suffice it to say that I checked all the boxes for meeting a stringent Daubert analysis.  First, my methodology was "reliable" because it involved a Westlaw search that included all the products liability key words for these types of products: agricultural, construction, mining, "industrial equipment," "products liability," "strict liability," "breach of warranty," negligence...and the list goes on.  After entering all of these words into the legal database, it generated well over 200 cases in both state and federal court from 2010.  To ensure the "relevance" of the cases, I then skimmed all of them to make a first cut at whittling the list down to about thirty cases that really seemed to focus on this type of equipment and involve substantive legal issues.  From these cases, I selected ten that I thought were the most interesting.  After that, I read and briefed all the cases, which is what is set forth in the written materials. 

Hey, if you went through this drill, I am sure you would probably come up with a different list.  However, I doubt you want to take that kind of time when I have done the work for you.  These are the ones I came up with, and hopefully you find them to be of interest if you work with these types of products.

This post is subject to the DISCLAIMER AND TERMS OF USE of this website.

Thursday, April 14, 2011

Upcoming DRI Drug and Medical Device Seminar in Chicago, Illinois on May 5-6, 2011

I am happy to post information about legal conferences pertaining to products liability issues. I always try to provide products liability information that is useful to the defense bar, plaintiff's bar, manufacturers, and individuals. Therefore, if anyone has a seminar or conference (regardless of whether it is defense or plaintiff-oriented), please pass it along and I will be happy to post the pertinent information.

The Defense Research Institute is holding their annual Drug and Medical Device Conference at the Sheraton Chicago in Chicago, Illinois on May 5-6, 2011.  It has been quite a few years since I attended this conference (last went to it in 2005 when it was in New York...a good time), but it is a must-attend if you defend drug and medical device manufacturers and sellers.

All the details for the conference, including a brochure of the agenda, registration, etc., can be found here.

Cut and paste of the information from DRI's website follows:

Overview
DRI’s Drug and Medical Device Seminar is the preeminent program for lawyers who represent pharmaceutical and medical device manufacturers. We are pleased again to feature a number of nationally recognized attorneys, both in-house and outside counsel, and other professionals who will address cutting-edge topics that are relevant to all who practice in this area, whether they are associates, lead trial counsel or in-house attorneys. This year’s program will offer a mixture of presentations, including trial skills demonstrations, a panel discussion of a groundbreaking defense and litigation insights from leading defenders of drug and device cases. In addition to the outstanding program, there will be numerous networking opportunities, including our annual Young Lawyers Blockbuster. Be sure to register now to reserve your place in Chicago at DRI’s 27th annual Drug and Medical Device Seminar.
Registration
The registration fee is $895 for members and those who join DRI when registering and $1,125 for non-members. The registration fee includes CD-ROM course materials, continental breakfasts, refreshment breaks and networking receptions. If you wish to have your name appear on the registration list distributed at the conference and receive the course materials in advance, DRI must receive your registration by April 15, 2011 (please allow 10 days for processing mailed registrations). Registrations received after April 15, 2011, will be processed on-site.
In-house counsel are eligible for free registration to DRI seminars. In-house counsel are defined as licensed attorneys, who are employed exclusively by a corporation or other private sector organization, for the purpose of providing legal representation and counsel only to that corporation, its affiliates and subsidiaries. In order to qualify for free registration, the individual must also be a DRI member and a member of DRI’s Corporate Counsel Committee. Offer excludes DRI Annual Meeting.
Hotel
A limited number of discounted hotel rooms have been made available at the Sheraton Chicago Hotel and Towers, 301 East North Water Street, Chicago, Illinois 60611. For reservations, contact the hotel directly at 312.464.1000. Please mention DRI’s Drug and Medical Device Seminar to take advantage of the group rate of $255 Single/$285 Double. The hotel block is limited and rooms and rates are available on a first-come, first-served basis. You must make reservations by April 12, 2011, to be eligible for the group rate. Requests for reservations made after April 6 are subject to room and rate availability.
Travel Discounts
DRI offers discounted meeting fares on various major air carriers for DRI seminar attendees. To receive these discounts, please contact Hobson Travel Ltd., DRI’s official travel provider at 800.538.7464 or you can book your travel on online at RESX.com. If you are a first time user use dri as company, your first initial and last name as Member ID and leave password blank the first time you login to enter a password. As always, to obtain the lowest available fares, early booking is recommended.
Special Discounts
No special discounts are provided for the Diversity for Success or Young Lawyers Seminars, Fidelity and Surety Roundtable, Defending Drug and Medical Device Litigation Young Lawyer Primer, the DRI Annual Meeting, or any non-CLE DRI meeting. For all other seminars, the first and second registrations from the same firm or company are subject to the fees outlined above. The registration fee for additional registrants from the same firm or company is $50 off the member rate, regardless of membership status. All registrations must be received at the same time to receive the discount.
Refund Policy
The registration fee is fully refundable for cancellations received on or before April 15, 2011. Cancellations received after April 15 and on or before April 22, 2011, will receive a refund, less a $50 processing fee. Cancellations made after April 22 will not receive a refund, but the course materials on CD-ROM and a $100 certificate good for any DRI seminar within the next 12 months will be issued. All cancellations and requests for refunds must be made in writing. Fax to DRI’s Accounting Department at 312.795.0747. All refunds will be mailed within four weeks after the date of the conference. Substitutions may be made at any time without charge and must be submitted in writing.

Wednesday, April 13, 2011

Article Published in SCDTAA Publication "The Defense Line"

I am pleased to announce that my article entitled "Limits on the Duty to Warn in South Carolina Products Liability Law" was recently published in the Spring 2011 edition of The Defense Line, which is published by the South Carolina Defense Trial Attorneys' Association. You can find a .pdf of the article here.

As background, South Carolina Lawyer was kind enough to publish my article, "South Carolina Products Liability Law: What is South Carolina's Law on Warnings?" in its January 2011 edition. (See my post about this publication here). The original draft of the article was intended to be a comprehensive review of South Carolina warnings law, with the exception of the doctrine of preemption (which is a topic for an entirely different article by itself). The problem was that the article was extremely long and nearly double the word limitations requested by South Carolina Lawyer. To prepare it for publication, I had to cut a substantial amount of material from the section dealing with exceptions to and limitations on the duty to warn. My hope was that I could use this material to create a separate article and have it published in a different publication.

Fast forward to the Spring edition of The Defense Line, and there you have it: the "lost material" from the original article. This article has substantially more information on limitations/exceptions to the duty to warn in South Carolina than what was in the original South Carolina Lawyer article, with more case law and analysis. Enjoy.

This post is subject to the DISCLAIMER AND TERMS OF USE of this website.

Tuesday, April 12, 2011

De-Brief From 2011 DRI Products Liability Law Conference

I am back from the 2011 DRI Products Liability Law Conference in New Orleans. I had a great time at this year's conference and wanted to provide a quick re-cap of everything that went on.

I arrived in New Orleans at about 3:30 on Tuesday afternoon. After checking out the
Hilton New Orleans Riverside and walking around a bit, I attended the networking reception that evening and met numerous attorneys and vendors from across the country who do products liability work. I went to dinner with a large group of attorneys that evening, and we enjoyed a great meal at Mr. John's Steakhouse. I highly recommend the red snapper special. Crazy delicious. Fantastic meal and group of attorneys.

On Wednesday, I attended the full session, which began at 8:15 a.m. My favorite presentation of the entire conference was later that morning and was presented by
Richard S. Levick of Levick Strategic Communications. I have heard Richard speak before at a retreat at my prior law firm, and he is always extremely informative and very entertaining in discussing how to manage crisis communications in the world of litigation. He also has an excellent blog, entitled "BulletProofBlog: The Blog on Crisis Communications." After the morning session, I went to a "luncharound" with nine other attorneys at Palace Cafe, which was also very good. As I had learned from the previous night's dinner, good food is never "quick" in New Orleans, so we were a bit late for the afternoon session. When we returned, I attended the Manufacturer's Risk Prevention Specialized Litigation Group ("SLG") breakout meeting. After the breakout, I attended another networking reception, and dinner on Wednesday night was at Arnaud's with some of my friends and colleagues on the Agricultural, Construction, Mining and Industrial Equipment ("ACMIE") SLG. John Phelps entertained our table with some great war stories about litigation and politics in Arkansas.

Thursday was more of the same, and I attended the full session where
Mark Kircher gave a really good presentation on "High Tech Demonstrative Exhibits that Work." The presentation involved animations used in cases to prove the defense's theory of the case, and some of them were really impressive. After another luncharound with attorneys at Restaurant August, it was time to prepare for my presentation at the ACMIE SLG breakout session. Our breakout session was two hours during the afternoon and the primary focus was on equipment fire cases. We had some great speakers, including John Phelps, representatives of John Deere and Caterpillar, and a forensic fire investigator. My presentation lasted approximately 20 minutes as was entitled "Who Needs Letterman? The Annual ACMIE Top 10 Cases." (I hope to post a link to the written materials once I get them on my biography website, but in the meantime, email me if you would like a copy of the written materials I prepared for my presentation). We got very good feedback from the SLG attendees after the session on all of the presentations. After another networking reception that evening, I went to Tommy's Cuisine with Lois Yamaguchi, Amy Fischer, Larry Ottaway, and Beth Anderson. Lois, Amy and Larry are attorneys affiliated with the Primerus group of law firms (of which Collins & Lacy, P.C. is a proud member), and Beth is an engineer with Anderson Engineering of New Prague, Inc. We had a great meal, and I would say that Tommy's was probably my favorite restaurant from the entire time I was in New Orleans.

Friday was the end of the conference, and I attended the Products Liability Committee meeting. Planning has already begun for next year's conference, and my congratulations to
Nick Pappas, outgoing ACMIE SLG Chairman, who was selected to head up the planning of next year's conference in Las Vegas. I look forward to attending and hope to play a role in the planning of next year's activities.

Wednesday, March 23, 2011

Jury Reaches Verdict in South Carolina Attorney General's Lawsuit Against Johnson & Johnson

Yesterday I posted an update about the South Carolina Attorney General's lawsuit against Johnson & Johnson and how the case went to the jury for deliberation (and the link to that post is here). The same reporters who provided news coverage about the closing arguments posted another article late yesterday that the jury reached a verdict, and their conclusion was that Johnson & Johnson violated South Carolina's consumer protection laws by sending South Carolina doctors a misleading letter about the safety and effectiveness of the anti-psychotic drug Risperdal.

A link to the article can be found here, and a cut and paste of it is below. (Thanks again to Bloomberg.com and these reporters for the coverage).

J&J’s Risperdal Letter Violated Consumer Law, Jury Finds


By Jef Feeley and Gary Henderson - Mar 22, 2011 7:23 PM ET

A Johnson & Johnson (JNJ) unit violated consumer-protection laws by sending South Carolina doctors a misleading letter about the safety and effectiveness of the antipsychotic drug Risperdal, a jury concluded.

Jurors in state court in Spartanburg, South Carolina, deliberated more than six hours before finding today that J&J’s Ortho-McNeil-Janssen Pharmaceuticals unit engaged in “unfair and deceptive acts” by sending a 2003 letter touting Risperdal as better and safer than competing drugs to more than 7,000 doctors across the state. A judge will decide later whether the drugmaker should pay $360 million in penalties over the mailings.

“The verdict they handed down is just and speaks the truth,” John White, a Spartanburg-based lawyer representing the state, said in an interview. Jurors also found that J&J warning label information on Risperdal was deceptive.

The state’s case centered on drug-safety claims that New Brunswick, New Jersey-based J&J and Janssen made in November 2003 correspondence to about 700,000 doctors across the U.S., including 7,200 in South Carolina.

The U.S. Food and Drug Administration responded with a warning letter saying J&J made false and misleading claims that minimized the potentially fatal risks of diabetes and overstated the drug’s superiority to competitors’ products.

‘Acted Responsibly’


“We are disappointed,” Greg Panico, a J&J spokesman, said in a statement. “Janssen acted responsibly and believes it did not violate” South Carolina law, he said.

South Carolina officials argued in the case that J&J sent the letter to protect billions of dollars in sales of the antipsychotic drug.

Risperdal’s global sales peaked at $4.5 billion in 2007 and declined after the company lost patent protection. Risperdal generated $3.4 billion in sales in 2008, or 5.4 percent of J&J’s total sales, according to company filings. Sales of the drug fell to $527 million last year, J&J said in a January earnings report.

Risperdal Consta, the long-acting version of the antipsychotic drug, generated $1.5 billion in sales last year for J&J.

The case is the third of about 10 state lawsuits to be considered by jurors over J&J’s Risperdal marketing campaigns. In June, J&J won dismissal of Pennsylvania’s suit alleging the company hid the drug’s diabetes risk and tricked regulators into paying millions more than they should have for the medicine.

Louisiana Verdict


A Louisiana jury ordered the drugmaker in October to pay $257.7 million in damages to that state for making misleading claims about Risperdal’s safety. A judge later added $73 million in legal fees to the award.

A West Virginia judge in a 2009 non-jury trial awarded $3.95 million, finding the company misled doctors about the risks and benefits of Risperdal. The state dropped its Risperdal claim after J&J won an appeal, company officials said in February.

Under South Carolina’s unfair trade practices law, Janssen can be fined as much as $5,000 for each Risperdal letter sent to South Carolina doctors. Judge Roger Couch will decide the financial-penalty issue after an April 18th hearing.

“After the judge makes a determination as to damages, we will consider our options,” Panico said in his statement.

The case is State of South Carolina v. Janssen Pharmaceuticals, 2007-CP-4201438, Circuit Court for Spartanburg County, South Carolina (Spartanburg).

To contact the reporters on this story: Jef Feeley in Wilmington, Delaware, at
jfeeley@bloomberg.net ; Gary Henderson in Spartanburg, South Carolina at wgaryh@gmail.com .

To contact the editor responsible for this story: David E. Rovella at
drovella@bloomberg.net .

This post is subject to the DISCLAIMER AND TERMS OF USE of this website.

Tuesday, March 22, 2011

Reminder: 2011 DRI Products Liability Conference Coming Up April 6-8, 2011

I previously posted all of the information about the upcoming 2011 DRI Products Liability Conference here, and I have been asked to post a reminder since we are only a couple of weeks away.

The
Defense Research Institute is holding their Products Liability Conference at the Hilton New Orleans Riverside in New Orleans, Louisiana this year from Wednesday, April 6 through Friday, April 8, 2011. This is a great conference. I went to the one last year that was in Las Vegas, and I am attending this year's conference. In fact, I will be presenting on Thursday at one of the Specialized Litigation Group ("SLG") breakout sessions. I joined the "Agricultural/Construction/Mining/Industrial Equipment" ("ACMIE") SLG last year, and this year I am doing a presentation entitled "Who Needs Letterman? The Annual ACMIE Top 10 Cases." As the title suggests, the presentation is basically a survey of significant cases in 2010 that involved ACMIE products and equipment (and if you know of a case that I should consider for inclusion, please comment so that I can get in touch and discuss it with you).

All the details for the conference, including a brochure of the agenda, registration, etc., can be found
here. I'm flying in Tuesday for the networking reception that evening, and I look forward to seeing anyone else who will be there.

Update: South Carolina Attorney General's Lawsuit Against Johnson and Johnson to Begin Jury Deliberations

This is an update to the post below in which I provided an article about the beginning of the South Carolina Attorney General's lawsuit against Johnson & Johnson about the drug Risperdal. According to the article below written by Jef Feeley and Gary Henderson, the jury will begin deliberations in the trial today. The article is a good account of the closing arguments during trial, and the direct link to the article is here. (Thanks to Bloomberg.com for the coverage).

J&J Duped South Carolina Doctors Over Risperdal, Lawyer Says

By Jef Feeley and Gary Henderson - Mar 21, 2011 5:38 PM ET

Johnson & Johnson executives deceived South Carolina doctors about the safety of the antipsychotic drug Risperdal, and the drugmaker should be held liable for that deception, a lawyer said.

J&J made misleading claims about Risperdal’s health risks and effectiveness in a letter to more than 7,000 South Carolina doctors and that violated consumer protection laws, John Simmons, a lawyer for the state, said in closing arguments of the trial of a lawsuit seeking at least $360 million in penalties.

The drugmaker, based in New Brunswick, New Jersey, used “unfair and deceptive acts” in a marketing campaign designed to dupe doctors into signing off on Risperdal for mental-health patients, Simmons told jurors today.

The state’s case centers on drug-safety claims that J&J and its Ortho-McNeil-Janssen Pharmaceuticals unit made in November 2003 correspondence to 700,000 doctors across the U.S., including 7,200 in South Carolina. The U.S. Food and Drug Administration responded with a warning letter saying J&J made false and misleading claims that minimized the potentially fatal risks of diabetes and overstated the drug’s superiority to those from competitors.

J&J contends the state hasn’t proved the company set out to mislead doctors about Risperdal or started a “spin campaign” to bolster sales of the drug, Steven J. Pugh, one of the drugmaker’s lawyers, said in his closing statement.

Fall in Sales

South Carolinians with mental-health issues “have benefited from Risperdal,” Pugh said. “You haven’t heard that anyone in South Carolina has been harmed by Risperdal.”

Risperdal’s global sales peaked at $4.5 billion in 2007 and declined after the company lost patent protection. It generated $3.4 billion in sales in 2008, or 5.4 percent of J&J’s total sales, according to company filings. Sales of the drug fell to $527 million last year, according to a January earnings report.

Risperdal Consta, the long-acting version of the antipsychotic drug, generated $1.5 billion in sales last year for Johnson & Johnson (JNJ), officials said this month.

Under South Carolina’s unfair trade practices law, if jurors decide Johnson & Johnson deceived doctors about Risperdal in the 2003 letter, the company can be fined as much as $5,000 for each letter. Judge Roger Couch will decide the financial- penalty issue after jurors hand down their decision.

Third Jury Trial

The case is the third of about 10 state lawsuits to be considered by jurors over J&J’s Risperdal marketing campaigns. In June, J&J won dismissal of Pennsylvania’s suit alleging the company hid the drug’s diabetes risk and tricked regulators into paying millions more than they should have for the medicine.

A Louisiana jury ordered the drugmaker in October to pay $257.7 million in damages to that state for making misleading claims about Risperdal’s safety. A judge later added $73 million in legal fees to the award.

A West Virginia judge in a 2009 non-jury trial awarded $3.95 million, finding the company misled doctors about the risks and benefits of Risperdal. The state dropped its Risperdal claim after J&J won an appeal, company officials said in February.

J&J’s Risperdal letter to doctors was part of a campaign to protect billions of dollars in sales of the antipsychotic drug and showed a lack of concern for the safety of South Carolina patients who took the drug, Simmons said.

The drugmaker set up a “spin machine” to deceive doctors about the drug and hid studies casting doubt on the medication’s safety and effectiveness, the lawyer said. “It was all about the money,” he added.

‘Send a Message’

“You have the power to send a message to these companies that you can’t hide stuff,” Simmons said. “Tell them, no unethical, immoral conduct in South Carolina.”

The Risperdal letter in the state’s crosshairs isn’t a proper basis for the attorney general’s claims that the drugmaker violated consumer-protection laws, Pugh countered.

The FDA warned J&J in 2004 to correct some things in the letter, but never formally sanctioned the drugmaker for sending it out, the lawyer added.

“The November 2003 letter was true then and it’s true now,” Pugh said. Risperdal is different from other antipsychotic medicines and “doctors needed to know that,” he added.

Jurors will begin deliberating the case tomorrow.

The case is State of South Carolina v. Janssen Pharmaceuticals, 2007-CP-4201438, Circuit Court for Spartanburg County, South Carolina (Spartanburg).

To contact the reporters on this story: Jef Feeley in Wilmington, Delaware, at
jfeeley@bloomberg.net Gary Henderson in Spartanburg, South Carolina at wgaryh@gmail.com.

To contact the editor responsible for this story: David E. Rovella at
drovella@bloomberg.net.

This post is subject to the DISCLAIMER & TERMS OF USE of this website.